Launch of Generic Niaspan® Extended-Release Tablets

Teva Pharmaceuticals has launched generic Niaspan® Extended-Release Tablets, which received FDA Approval in April 2005 and can now be released based on a settlement with the brand manufacturer.

Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Estimated annual U.S. brand sales of this product are $1.129 billion.